Together, our findings give rise to the hypothesis for the first time that by interacting with ENO1, irisin may inhibit the proliferation and remodeling of PAH, which may in turn make irisin as a promising biomarker and a potential therapeutic target for PAH. This evidence concerns the gene FNDC5 and pulmonary arterial hypertension.